MRTX News and Press, Mirati Therapeutics Inc. From 07/21/23

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , July 21, 2023 /PRNews...

2023-07-07 11:10:00 ET Vancouver, Kelowna, Delta, BC - July 7, 2023 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech. Today's stocks have been added to our lists of free stock ...

Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director PR Newswire SAN DIEGO , June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today ...

2023-06-22 10:30:47 ET Palm Beach, FL – June 22, 2023 – FinancialNewsMedia.com News Commentary – Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is ...

Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases PR Newswire Adagrasib is the first and only KRAS G12C inhibitor to prospectively demonstrate int...

Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 PR Newswire SAN DIEGO , June 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will part...

Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting PR Newswire Data follows recent inclusion of Adagrasib in NCCN Guidelines for PDAC and CNS Cancers ...

2023-05-25 15:23:24 ET Mirati Therapeutics ( NASDAQ: MRTX ) shed ~12% on Thursday after the biotech said its lung cancer therapy sitravatinib, in combination with Bristol-Myers Squibb's ( BMY ) Opdivo, failed to reach the primary endpoint in a Phase 3 trial. However,...

2023-05-25 10:04:19 ET Gainers: Absci ( ABSI ) +17% . Predictive Oncology ( POAI ) +10% . Cardio Diagnostics ( CDIO ) +8% . Ocean Biomedical ( OCEA ) +8% . HeartBeam ( BEAT ) +7% . Losers: Annexon ( ANNX ) -57% .&#...

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO® PR Newswire SAN DIEGO , May 24, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial-stage oncology co...